ViaDerma (VDRM) News Today $0.0075 0.00 (-5.06%) (As of 12/27/2024 05:50 PM ET) Add Compare Share Share Headlines Stock AnalysisChartShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ViaDerma, Inc. (OTCMKTS:VDRM) Short Interest UpdateDecember 28 at 3:45 AM | americanbankingnews.comViaDerma Announces Significant 2024 Achievements and International ExpansionDecember 10, 2024 | markets.businessinsider.comViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow GrowthOctober 3, 2024 | finance.yahoo.comViaDerma Completes First Shipment of 500,000 Units to NigeriaSeptember 10, 2024 | stockhouse.comViaDerma Announces Shipment of 500,000 Units of its Flagship Product to NigeriaAugust 14, 2024 | finance.yahoo.comViaDerma Announces Shipment of 500,000 Units of its Flagship Product to NigeriaAugust 13, 2024 | globenewswire.comViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key HiresAugust 1, 2024 | globenewswire.comViaDerma Provides Highlights of Quarterly Financial ReportJune 6, 2024 | globenewswire.comViaDerma, Inc. (VDRM)May 16, 2024 | finance.yahoo.comViaDerma Inc VDRMMarch 3, 2024 | morningstar.comViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & MoreOctober 24, 2023 | finance.yahoo.comViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & MoreJuly 6, 2023 | finance.yahoo.comViaDerma, Inc. (VDRM) Stock Historical Prices & Data - Yahoo FinanceApril 18, 2023 | finance.yahoo.comViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth ProductMarch 16, 2023 | finance.yahoo.comViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth ProductMarch 8, 2023 | finance.yahoo.comViaDerma Provides an Update on Current & Future Business ActivitiesMarch 2, 2023 | finance.yahoo.comViaDerma Retains Digital Marketing Leader INTENT SCIENCES to Accelerate Business Growth OnlineJanuary 12, 2023 | benzinga.comViaDerma Successfully Completes Quality Control Testing of its New Vitastem ProductsSeptember 15, 2022 | finance.yahoo.comViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem ProductsJune 22, 2022 | finance.yahoo.comAvoteo emerges as the first crowdfunding platform without spending moneyApril 1, 2022 | nz.finance.yahoo.comVictoria and David Beckham's UK home 'burgled' while daughter Harper was asleep upstairsApril 1, 2022 | yahoo.comOur existence isn't new, but now transgender people are visible like never beforeApril 1, 2022 | yahoo.comViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous YearMarch 31, 2022 | finance.yahoo.comViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem UltraOctober 4, 2021 | finance.yahoo.comViaDerma, Inc. Files Amended Financial StatementsAugust 24, 2021 | finance.yahoo.comViaDerma Inc.August 21, 2021 | barrons.com Get ViaDerma News Delivered to You Automatically Sign up to receive the latest news and ratings for VDRM and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. VDRM Media Mentions By Week VDRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VDRM News Sentiment▼-0.010.58▲Average Medical News Sentiment VDRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VDRM Articles This Week▼20▲VDRM Articles Average Week Get ViaDerma News Delivered to You Automatically Sign up to receive the latest news and ratings for VDRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Algernon Pharmaceuticals News Allstar Health Brands News American Premium Mining News Anew Medical News Arno Therapeutics News AstraZeneca News AVVAA World Health Care Products News biote News BriaCell Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:VDRM) was last updated on 12/29/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViaDerma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ViaDerma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
